$CORT
Corcept Therapeutics Inc

2019 Q4 Form 10-Q Financial Statement

#000162828019013716 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q4
Revenue $87.90M $81.51M $66.83M
YoY Change 31.52% 26.47% 25.43%
Cost Of Revenue $1.440M $1.451M $1.580M
YoY Change -8.86% 10.93% 36.21%
Gross Profit $86.46M $80.05M $65.25M
YoY Change 32.5% 26.79% 25.19%
Gross Profit Margin 98.37% 98.22% 97.64%
Selling, General & Admin $27.13M $24.25M $21.56M
YoY Change 25.83% 13.78% 28.33%
% of Gross Profit 31.38% 30.29% 33.04%
Research & Development $24.31M $22.81M $18.79M
YoY Change 29.38% 20.92% 37.86%
% of Gross Profit 28.12% 28.49% 28.8%
Depreciation & Amortization $200.0K $200.0K $0.00
YoY Change 100.0%
% of Gross Profit 0.23% 0.25% 0.0%
Operating Expenses $51.44M $47.05M $40.35M
YoY Change 27.48% 17.13% 32.64%
Operating Profit $35.02M $33.00M $24.90M
YoY Change 40.63% 43.69% 14.74%
Interest Expense $1.440M $1.350M $1.040M
YoY Change 38.46% 77.63%
% of Operating Profit 4.11% 4.09% 4.18%
Other Income/Expense, Net $1.348M
YoY Change 77.6%
Pretax Income $36.46M $34.35M $25.94M
YoY Change 40.56% 44.77% 18.5%
Income Tax $7.080M $8.000M $3.930M
% Of Pretax Income 19.42% 23.29% 15.15%
Net Earnings $29.38M $26.34M $22.01M
YoY Change 33.5% 48.42% -77.62%
Net Earnings / Revenue 33.43% 32.32% 32.93%
Basic Earnings Per Share $0.26 $0.23 $0.19
Diluted Earnings Per Share $0.24 $0.22 $0.18
COMMON SHARES
Basic Shares Outstanding 114.3M shares 113.9M shares 115.5M
Diluted Shares Outstanding 121.8M shares

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $276.0M $231.6M $206.8M
YoY Change 33.47% 18.65% 132.98%
Cash & Equivalents $31.27M $44.95M $41.63M
Short-Term Investments $244.7M $186.7M $165.1M
Other Short-Term Assets $6.000M $7.800M $7.700M
YoY Change -22.08% 81.4% 185.19%
Inventory $5.424M $5.462M $4.732M
Prepaid Expenses
Receivables $19.93M $22.41M $17.59M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $307.4M $267.3M $236.8M
YoY Change 29.79% 19.23% 90.7%
LONG-TERM ASSETS
Property, Plant & Equipment $1.050M $1.227M $655.0K
YoY Change 60.31% 145.4% 26.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $39.40M $35.30M $0.00
YoY Change 2253.33% -100.0%
Other Assets $3.448M $150.0K $50.00K
YoY Change 6796.0% 183.02% 0.0%
Total Long-Term Assets $105.0M $99.71M $74.87M
YoY Change 40.17% 31.98% -22.29%
TOTAL ASSETS
Total Short-Term Assets $307.4M $267.3M $236.8M
Total Long-Term Assets $105.0M $99.71M $74.87M
Total Assets $412.3M $367.0M $311.7M
YoY Change 32.28% 22.44% 41.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.537M $5.937M $8.266M
YoY Change -8.82% -57.36% -3.65%
Accrued Expenses $23.27M $21.57M $23.79M
YoY Change -2.17% 3.24% 26.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.84M $32.40M $35.57M
YoY Change 9.19% -19.41% 20.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.300M $300.0K $200.0K
YoY Change 1050.0%
Total Long-Term Liabilities $2.300M $300.0K $200.0K
YoY Change 1050.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.84M $32.40M $35.57M
Total Long-Term Liabilities $2.300M $300.0K $200.0K
Total Liabilities $41.13M $32.65M $35.81M
YoY Change 14.85% -18.79% 21.11%
SHAREHOLDERS EQUITY
Retained Earnings -$23.56M -$52.94M -$117.7M
YoY Change -79.99% -62.12% -39.04%
Common Stock $457.2M $446.7M $417.3M
YoY Change 9.54% 9.42% 8.63%
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.66M
YoY Change
Treasury Stock Shares
Shareholders Equity $371.2M $334.4M $275.9M
YoY Change
Total Liabilities & Shareholders Equity $412.3M $367.0M $311.7M
YoY Change 32.28% 22.44% 41.33%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q4
OPERATING ACTIVITIES
Net Income $29.38M $26.34M $22.01M
YoY Change 33.5% 48.42% -77.62%
Depreciation, Depletion And Amortization $200.0K $200.0K $0.00
YoY Change 100.0%
Cash From Operating Activities $48.40M $38.50M $21.60M
YoY Change 124.07% -13.48% -12.9%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$300.0K -$100.0K
YoY Change 0.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$61.80M -$54.00M -$1.700M
YoY Change 3535.29% 61.68% -93.8%
Cash From Investing Activities -$62.00M -$54.30M -$1.800M
YoY Change 3344.44% 62.09% -93.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K 2.700M -12.00M
YoY Change -99.17% -132.53% -580.0%
NET CHANGE
Cash From Operating Activities 48.40M 38.50M 21.60M
Cash From Investing Activities -62.00M -54.30M -1.800M
Cash From Financing Activities -100.0K 2.700M -12.00M
Net Change In Cash -13.70M -13.10M 7.800M
YoY Change -275.64% -585.19% -4000.0%
FREE CASH FLOW
Cash From Operating Activities $48.40M $38.50M $21.60M
Capital Expenditures -$100.0K -$300.0K -$100.0K
Free Cash Flow $48.50M $38.80M $21.70M
YoY Change 123.5% -13.0% -12.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-16000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
25000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-123000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114280708 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44948000 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1227000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
655000 USD
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000 USD
CY2019Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
35250000 USD
CY2019Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
250000 USD
CY2018Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
239000 USD
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
50000 USD
CY2019Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
50804000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
62659000 USD
CY2019Q3 us-gaap Assets
Assets
367022000 USD
CY2018Q4 us-gaap Assets
Assets
311694000 USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q3 us-gaap Liabilities
Liabilities
32646000 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5937000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8266000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
184416000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41625000 USD
CY2019Q3 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4121000 USD
CY2018Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3521000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1451000 USD
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1308000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21568000 USD
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
186697000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165135000 USD
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22405000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17588000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
5462000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
4732000 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7798000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
35812000 USD
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7740000 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52936000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117736000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
66213000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8012000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
334376000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23786000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275882000 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367022000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4068000 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
267310000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
236820000 USD
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11539000 USD
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11510000 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
742000 USD
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32396000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35573000 USD
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
119000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
117000 USD
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
446611000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
417228000 USD
CY2019Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
59732000 USD
CY2018Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
23657000 USD
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
314000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-70000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311694000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5981000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81505000 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64445000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
218591000 USD
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
389000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3636000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22805000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18860000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64705000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56453000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24245000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15416000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12811000 USD
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21308000 USD
us-gaap Net Income Loss
NetIncomeLoss
64800000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
17747000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73228000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59729000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
48501000 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
41476000 USD
us-gaap Costs And Expenses
CostsAndExpenses
142001000 USD
us-gaap Costs And Expenses
CostsAndExpenses
119818000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
33004000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
22969000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
76590000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
64598000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1348000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
759000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3626000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1615000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
34352000 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
23728000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
80216000 USD
us-gaap Net Income Loss
NetIncomeLoss
53402000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26333000 USD
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17797000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
65184000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53325000 USD
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-12896000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
58000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1606000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
100000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6643000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6600000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
163000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1136000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4817000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4060000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
0 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
168445000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
88500000 USD
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113875000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114349000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115394000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121762000 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126159000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122478000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127167000 shares
us-gaap Profit Loss
ProfitLoss
64800000 USD
us-gaap Profit Loss
ProfitLoss
53402000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
21703000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
17481000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11731000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10602000 USD
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1413000 USD
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1020000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
474000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
654000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4346000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2424000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5343000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
600000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
3145000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2207000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2149000 USD
cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1108000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87663000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
94146000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
953000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6017000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
17459000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223331000 USD
CY2018Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
24000 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6510000 USD
CY2018Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
51000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
177325000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55839000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
215226000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-89010000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4044000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
931000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
0 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
1878000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
190968000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1922000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4954000 USD
CY2018Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-77000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
18196000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
243507000 USD
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
634000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
30975000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8904000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4169000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28501000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2304000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3323000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2832000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41625000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31062000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44948000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33894000 USD
CY2018Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8904000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
17747000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
259545000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275882000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3366000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5100000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6724000 USD
CY2019Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
164000 USD
CY2019Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
13555000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
285755000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1514000 USD
CY2018Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
16242000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7791000 USD
CY2019Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
227000 USD
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17420000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
20186000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
298053000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2697000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7293000 USD
CY2019Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-7000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
334376000 USD
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2018 cort Number Of Compounds
NumberOfCompounds
500 compound
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
472000 USD
CY2019Q3 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
0 USD
CY2018Q4 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
4195000 USD
CY2019Q3 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
13033000 USD
CY2018Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
5624000 USD
CY2019Q3 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
3968000 USD
CY2018Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6423000 USD
CY2019Q3 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17001000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
240000 USD
CY2019Q3 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
244000 USD
CY2018Q4 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
2032000 USD
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
974000 USD
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1542000 USD
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
552000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
386000 USD
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11539000 USD
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11510000 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
5462000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
4732000 USD
CY2019Q3 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
8024000 USD
CY2018Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
11132000 USD
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8262000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7879000 USD
CY2019Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2033000 USD
CY2018Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
261000 USD
CY2019Q3 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
1007000 USD
CY2018Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
314000 USD
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21568000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23786000 USD
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
252091000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
192210000 USD
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P7M
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 USD
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
391000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1160000 USD
CY2019Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1878000 USD
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6M
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6M
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
391000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
391000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
782000 USD
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
770000 USD
CY2019Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 USD
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 USD
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
2 stock_option_plan
CY2019Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
22000 USD
CY2018Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
105000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
7293000 USD
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
6510000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21808000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
17481000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
17747000 USD
us-gaap Net Income Loss
NetIncomeLoss
64800000 USD
us-gaap Net Income Loss
NetIncomeLoss
53402000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113875000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115798000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114349000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115394000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7887000 shares
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10361000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8129000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
11773000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121762000 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126159000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122478000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127167000 shares
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24100000 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23300000 shares
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000000.0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15400000 USD
CY2019Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
500000 USD
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3600000 USD
CY2019Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-5900000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-11700000 USD
CY2019Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2100000 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
3700000 USD
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000000.0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12800000 USD
CY2018Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-5000000.0 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-10600000 USD
CY2018Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1000000.0 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2200000 USD

Files In Submission

Name View Source Status
0001628280-19-013716-index-headers.html Edgar Link pending
0001628280-19-013716-index.html Edgar Link pending
0001628280-19-013716.txt Edgar Link pending
0001628280-19-013716-xbrl.zip Edgar Link pending
cort-20190930.xsd Edgar Link pending
cort-20190930_cal.xml Edgar Link unprocessable
cort-20190930_def.xml Edgar Link unprocessable
cort-20190930_lab.xml Edgar Link unprocessable
cort-20190930_pre.xml Edgar Link unprocessable
cort9301910-qdoc.htm Edgar Link pending
cort9301910-qdoc_htm.xml Edgar Link completed
cort93019ex311.htm Edgar Link pending
cort93019ex312.htm Edgar Link pending
cort93019ex321.htm Edgar Link pending
cort93019ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending